Introducing Medisca Nutraceuticals

Download in electronic PDF format for $25



Search the Complete Journal Archives

Litigating the Legality of Compounding: The Medical Center Pharmacy Case

Author(s):  Gibbs Jeffrey N

Issue:  May/Jun 2008 - Pain Management
View All Articles in Issue

Abstract:  The question of whether all compounded drugs are “new drugs” has been disputed in the United States for over 15 years. The Federal Food, Drug, and Cosmetic Act generally requires that “new drugs” obtain U.S. Food and Drug Administration approval before being sold in the U.S. Between 1938 and the late 1980s, the U.S. Food and Drug Administration did not assert that compounded drugs are subject to the new drug provisions. Then, the U.S. Food and Drug Administration developed and advanced a new theory. As articulated in a 1989 memorandum by a U.S. Food and Drug Administration attorney, the U.S. Food and Drug Administration could take the position that compounded drugs were new drugs and therefore subject to new drug approval requirements. Although the memorandum acknowledged that this represented a significant change in policy, the U.S. Food and Drug Administration adopted this legal theory. Their position that compounded drugs are new drugs led to a clash between the agency and compounding pharmacies. Congress

Related Keywords: Jeffrey N. Gibbs, BA, JD, pharmacy regulation, pharmacy law, legal cases, U.S. Food and Drug Administration, FDA, unapproved new drugs

Related Categories: LEGAL, PROFESSIONAL ISSUES

Printer-Friendly Version

Related Articles from IJPC
Title (Click for Abstract / Details) Author Issue Page View/Buy
Litigating the Legality of Compounding: The Medical Center Pharmacy Case Gibbs Jeffrey N May/Jun 2008 238-241 Buy
Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines Allen Loyd V Jr Jul/Aug 2016 351 View Sample
PostScription: Thousands of Unapproved New Drugs are on the U.S. Market, Part 1 Allen Loyd V Jr Jul/Aug 2007 350-351 Buy
U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs Allen Loyd V Jr Nov/Dec 2015 487-488 Buy
U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances Miller David G Jul/Aug 2015 303-305 Buy
PostScription: Thousands of Unapproved New Drugs are on the U.S. Market, Part 2 Allen Loyd V Jr Sep/Oct 2007 438-439 Buy
Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1 Allen Loyd V Jr Sep/Oct 2015 389-390 Buy
The U.S. Food and Drug Administration Responds to the International Academy of Compounding Pharmacists' Outsourcing Letter Miller David G May/Jun 2014 208 Buy
Compounding OTC Drugs: A Legal Perspective Gibbs Jeffrey N, Mazan Kate Duffy May/Jun 2000 180 Buy
U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List) Nov/Dec 2016 457-458 Buy